Metabolic syndrome and C-reactive protein in patients with depressive disorder on antidepressive medication

Stanojević, Albina; Popović, Iva; Nenadović, M.; Ravanic, D.; Paunovic-Milosavljevic, Gordana

doi:10.2298/sarh1308511s

Cited by 3 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some authors showed a positive correlation and normalization of these values after therapy with antidepressants [ 59 , 60 ]. However, these finding were not consistent with negative findings from other studies in this field [ 52 ].…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants

et al. 2016

View full text Add to dashboard Cite

BackgroundIt is still disputable whether negative effects of comorbid depression in diabetics can be diminished by successful treatment of depression. The primary aim of this study was to assess whether addition of antidepressants to existing insulin treatment would further improve glycemic control in these patients. A secondary objective was to assess whether such treatment impairs their lipid and inflammatory status.Material/MethodsTotal of 192 patients with poorly controlled diabetes (defined as HbA1c ≥8%) in the absence of any uncontrolled medical condition entered the 6-month run-in phase with optimization of diabetic therapy. Depression status was screened at the end of this phase by BDI-II depression testing. Patients with BDI-II ≥14 and psychiatric confirmation of depression (58 patients) entered the 6-month interventional phase with SSRI class antidepressants.ResultsFifty patients completed the study. During the run-in phase, HbA1c dropped from 10.0±1.8% to 8.5±1.2% (p<0.001), and during the interventional phase it dropped from 8.5±1.2% to 7.7±0.7% (p<0.001). BDI-II scores improved significantly from 30.4±13.2 to 23.5±11.0 (p=0.02) during the interventional phase. A positive linear correlation between improvement in depression scale and improvement in glycemic control was observed (R2=0.139, p=0.008). Lipid profile and inflammatory status did not change significantly during the interventional phase.ConclusionsPatients with poorly controlled diabetes and comorbid depression might benefit from screening and treatment of depression with SSRI antidepressants by achieving an incremental effect on glycoregulation. This therapy did not have any adverse effects on lipid profile or inflammatory status.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…CRP is one of the positive acute-phase proteins, secreted in the liver. Depression has been shown to be associated with the increased inflammatory response [ 52 ]. Also, it has been suggested that the link between depression, obesity, and diabetes may be mediated through inflammation.…”

Section: Discussionmentioning

confidence: 99%

Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The study by Stanojevic et al [ 83 ] showed the levels of total cholesterol, low-density lipoprotein cholesterol, triglycérides and blood pressure were statistically significantly elevated in the depressive patients with metabolic syndrome compared with healthy controls. Moreover, in other studies, hypercholesterolemia was linked to the poor outcome of antidepressant therapy in depression.…”

Section: Discussionmentioning

confidence: 99%

Predictive markers of depression in hypertension

Song

Zhang

et al. 2018

Medicine

View full text Add to dashboard Cite

Hypertension and depression, as 2 major public health issues, are closely related. For patients having hypertension, in particular, depression is a risk factor for mortality and jeopardizes their wellbeing. The aim of the study is to apply support vector machine (SVM) learning to blood tests and vital signs to classify patients having hypertension complicated by depression and patients having hypertension alone for the identification of novel markers.Data on patients having both hypertension and depression (n = 147) and patients having hypertension alone (n = 147) were obtained from electronic medical records of admissions containing the records on blood tests and vital signs. Using SVM, we distinguished patients having both hypertension and depression from gender- and age-matched patients having hypertension alone.SVM-based classification achieved 73.5% accuracy by 10-fold cross-validation between patients having both hypertension and depression and those having hypertension alone. Twelve features were selected to compose the optimal feature sets, including body temperature (T), glucose (GLU), creatine kinase (CK), albumin (ALB), hydroxybutyrate dehydrogenase (HBDH), blood urea nitrogen (BUN), uric Acid (UA), creatinine (Crea), cholesterol (TC), total protein (TP), pulse (P), and respiration (R).SVM can be used to distinguish patients having both hypertension and depression from those having hypertension alone. A significant association was identified between depression and blood tests and vital signs. This approach can be helpful for clinical diagnosis of depression, but further studies are needed to verify the role of these candidate markers for depression diagnosis.

show abstract

“…The PubMed literature search identified 36 articles. After title, abstract, and eventually full-text screening, 8 papers ( 1 , 37 – 43 ) met inclusion criteria for this mini-review (see Figure 1 for more details) ( 46 ).…”

Section: Resultsmentioning

confidence: 99%

“…Of the 8 studies included in our mini-review, 2 used a prospective cohort design ( 37 , 41 ), and 6 a cross-sectional design ( 1 , 38 – 40 , 42 , 43 ). In 3 studies the number of participants was ≤ 99 ( 38 , 40 , 43 ), 2 studies had a sample ranging from 100 to 240 individuals ( 37 , 41 ), 3 studies included more than 250 patients ( 1 , 39 , 42 ). The average number of participants was of 277 ± 296 (SD) (min 60, max 970 participants).…”

Section: Resultsmentioning

confidence: 99%

Increased Risk of Metabolic Syndrome in Antidepressants Users: A Mini Review

et al. 2018

View full text Add to dashboard Cite

Mounting evidence has shown that the risk of metabolic syndrome (MetS) is substantially overlapping in the diagnostic subgroups of psychiatric disorders. While it is widely acknowledged that patients receiving antipsychotic medications are at higher risk of MetS than antipsychotic-naive ones, the association between antidepressants and MetS is still debated. The goal of our mini review was to analyse the relationship among depressive symptoms, antidepressant use and the occurrence of MetS. Adhering to PRISMA guidelines, we searched MEDLINE, reference lists and journals, using the following search string: (((“Mental Disorders”[Mesh]) AND “Metabolic Syndrome”[Mesh]) AND “Antidepressive Agents”[Mesh]), and retrieved 36 records. Two reviewers independently assessed records and the mini review eventually included the data extracted from 8 studies. The Newcastle-Ottawa Scale was used to assess the quality of the selected studies. Overall, the results of the mini review seem to support the association among depressive symptoms, antidepressants therapy and MetS. Except for H1-R high-affinity ones, the relationship between antidepressants and MetS still needs to be clarified. Considering the widespread prescription of antidepressants, both on behalf of psychiatrists and primary care physicians, further research on this topic is recommended.

show abstract

Metabolic syndrome and C-reactive protein in patients with depressive disorder on antidepressive medication

Abstract: Both CRP levels and metabolic risk profile screening, according to the international criteria, may be beneficial in order to obtain better assessment for depressive long-term medicated patients.

Cited by 3 publications

References 26 publications

Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants

Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants

Predictive markers of depression in hypertension

Increased Risk of Metabolic Syndrome in Antidepressants Users: A Mini Review

Contact Info

Product

Resources

About